The recent FDA meeting revealed the increasingly complex challenges faced by genetic medicine companies in their quest to achieve profitability in the realm of intricate and expensive therapies. As the landscape of genetic medicine continues to evolve, biotech firms are being forced to reassess their strategies, with many scaling back research efforts, downsizing, or even […]
